All In Biotech

BLA 021859 · Halozyme Therap

Hylenex Recombinant

Hyaluronidase Recombinant Human · Injection · Endoglycosidase

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jan 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Dec 2, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

155

39 Phase 3, 16 recruiting

FAERS reports

1,227

1,022 serious, 548 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2024.

1. Indications and Usage HYLENEX recombinant is an endoglycosidase indicated as an adjuvant in subcutaneous fluid administration for achieving hydration ( 1.1 ) to increase the dispersion and absorption of other injected drugs ( 1.2 ) in subcutaneous urography for improving resorption of radiopaque agents ( 1.3 ) 1.1. Subcutaneous Fluid Administration HYLENEX recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. 1.2. Dispersion and Absorption of Injected Drugs HYLENEX recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs. 1.3. Subcutaneous Urography HYLENEX recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

Mechanism: Hyaluronidase is a dispersion agent, which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronic acid is also present in the capsules of type A and C hemolytic streptococci. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of an N-acetylglucosamine moiety and C4 of a glucuronic acid moiety. This temporarily decreases the viscosity of the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 2, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterLabel
1 products under this application
  • HYLENEX RECOMBINANT · HYALURONIDASE RECOMBINANT HUMAN 150 UNITS/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Hyaluronidase Recombinant Human" as an intervention, any sponsor and status, largest first.

All 155 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue305
  • abdominal discomfort298
  • alopecia294
  • diarrhoea282
  • asthenia281
  • arthralgia280
  • headache279
  • hypertension279
  • hypersensitivity278
  • hepatic enzyme increased275
  • contusion271
  • asthma270

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20058
200622
200727
20088
20099
20106
20118
20125
20132
201414
201545
201623
201731
201823
201929
202053
202167
202261
2023110
2024310
2025232
2026126

Recalls

1 FDA enforcement reports for this application.

  • Sep 11, 2024 · Class II · Terminated

    cGMP Deviations: Temperature excursion

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Halozyme Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.